|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 287 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- HIV-1 Infection Overview
- Therapeutics Development
- An Overview of Pipeline Products for HIV-1 Infection
- HIV-1 Infection Therapeutics under Development by Companies
- HIV-1 Infection Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- HIV-1 Infection Therapeutics – Products under Development by Companies
- HIV-1 Infection Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in HIV-1 Infection Therapeutics Development
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Abbott Laboratories
- GlaxoSmithKline plc
- Inovio Biomedical Corporation
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- United Biomedical, Inc.
- Aphios Corporation
- Pfizer Inc.
- Avexa Limited
- Koronis Pharmaceuticals, Inc.
- Alfacell Corporation
- Geron Corporation
- GeoVax Labs, Inc.
- ConjuChem Biotechnologies Inc.
- Critical Outcome Technologies Inc.
- Takara Bio Inc.
- Functional Genetics, Inc.
- BioClonetics Incorporated
- Nutri Pharma ASA
- Vironova AB
- Argos Therapeutics, Inc.
- Myriad Pharmaceuticals, Inc.
- GeneCure LLC
- Tobira Therapeutics, Inc.
- ViiV Healthcare
- RFS Pharma, LLC
- Vichem Chemie Research Ltd.
- HIV-1 Infection – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- 1265744 - Drug Profile
- MPI-461359 - Drug Profile
- pGA2/JS7 DNA Vaccine + Recombinant Modified Vaccinia Ankara/HIV62B Vaccine - Drug Profile
- Amdoxovir - Drug Profile
- TBR-652 - Drug Profile
- AGS-004 - Drug Profile
- Apricitabine - Drug Profile
- Raltegravir + Tenofovir + Lamivudine - Drug Profile
- Tenofovir + Emtricitabine + Efavirenz - Drug Profile
- Autologous HIV-1 ApB DC Vaccine - Drug Profile
- Lopinavir + Ritonavir - Drug Profile
- Dapivirine Ring - Drug Profile
- Zidovudine + Lamivudine + Nevirapine - Drug Profile
- Truvada + Darunavir + Ritonavir + Maraviroc + Raltegravir - Drug Profile
- Gardasil - Drug Profile
- Dendritic Cell Vaccine + GM-CSF + Interferon Alpha - Drug Profile
- mRNA-Transfected Autologous Dendritic Cells - Drug Profile
- MVA.HIVA Vaccine - Drug Profile
- Etravirine + Nucleoside + Nucleotide Reverse Transcriptase Inhibitors - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile
- VRC-HIVADV014-00-VP - Drug Profile
- Stavudine + Lamivudine + Abacavir - Drug Profile
- Emtricitabine + Tenofovir - Drug Profile
- Tenofovir - Drug Profile
- Stavudine + Lamivudine + Nevirapine - Drug Profile
- Abacavir + Lamivudine + Nevirapine - Drug Profile
- Zidovudine + Lamivudine + Abacavir - Drug Profile
- Emend - Drug Profile
- Didanosine + Abacavir + Kaletra - Drug Profile
- Zidovudine + Lamivudine + Kaletra - Drug Profile
- Lamivudine + Didanosine + Efavirenz - Drug Profile
- Lamivudine + Recombinant Hepatitis B Surface Antigen - Drug Profile
- Raltegravir + Lopinavir + Ritonavir - Drug Profile
- Isentress + Kaletra - Drug Profile
- Vacc-4x - Drug Profile
- Ad35-GRIN/ENV HIV Vaccine - Drug Profile
- VRC-HIVDNA-016-00-VP + VRCHIVADV014-00-VP - Drug Profile
- Atazanavir + Raltegravir + Lamivudine - Drug Profile
- Atazanavir + Raltegravir + Emtricitabine - Drug Profile
- Lopinavir + Ritonavir + Zidovudine - Drug Profile
- Abacavir + Zidovudine - Drug Profile
- BMS-663068 - Drug Profile
- BMS-663068 + Ritonavir - Drug Profile
- Darunavir + Ritonavir - Drug Profile
- Raltegravir + Darunavir + Etravirine + NRTIs + Enfuvirtide - Drug Profile
- TUTI-16 - Drug Profile
- Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile
- TMC310911 + Ritonavir - Drug Profile
- KP-1461 - Drug Profile
- Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile
- PENNVAX-B DNA Vaccine - Drug Profile
- EP HIV-1043 - Drug Profile
- EP HIV-1043 + EP HIV-1090 - Drug Profile
- EP HIV-1090 - Drug Profile
- rAd5 env A + rAd5 env B - Drug Profile
- GTU-MultiHIV B Clade Vaccine + Interleukin-2 + GM-CSF + Growth Hormone - Drug Profile
- PENNVAX-B + GENEVAX IL-12-4532 - Drug Profile
- PENNVAX-B + GENEVAX IL-12-4532 - Drug Profile
- SAAVI DNA-C2 Vaccine + SAAVI MVA-C Vaccine - Drug Profile
- Kaletra - Drug Profile
- Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile
- Viread + Aluvia - Drug Profile
- Truvada + Nevirapine - Drug Profile
- Truvada + Zidovudine - Drug Profile
- ALVAC-HIV vCP1521 - Drug Profile
- MVA.HIVconsv - Drug Profile
- TBC-M4 - Drug Profile
- AD100-GP96IG-HLA A1 Vaccine - Drug Profile
- ChAdV63.HIVconsv + pSG2.HIVconsv + MVA.HIVconsv - Drug Profile
- Fuzeon + Truvada + Kaletra - Drug Profile
- rAd35 Env A - Drug Profile
- rAd35 Env A + rAd5 Env A - Drug Profile
- rAd5 Env A - Drug Profile
- Tenofovir + Emtricitabine - Drug Profile
- GS-7340 - Drug Profile
- Isentress + Tenofovir + Lamivudine - Drug Profile
- HIV gp120/NefTat/AS02A Vaccine - Drug Profile
- ART Regimen + Raltegravir + Maraviroc - Drug Profile
- KD-247 - Drug Profile
- HIV-1 Integrase Inhibitor Program - Drug Profile
- ART Regimen + Raltegravir + Maraviroc + Interleukin-7 - Drug Profile
- Zinc Supplementation - Drug Profile
- Intelence + Truvada - Drug Profile
- Autologous CD4-ZETA Gene Modified T Cells + Interleukin-2 - Drug Profile
- Intelence + Ritonavir + Atazanavir + NRTI - Drug Profile
- UB-421 - Drug Profile
- HIV-1 Drug Development Programme - Drug Profile
- TAT0002 - Drug Profile
- Celsentri + Antiretroviral Therapy - Drug Profile
- UK-453061 + Tenofovir DF + Emtricitabine - Drug Profile
- DACHIV - Drug Profile
- Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile
- GSK732462 - Drug Profile
- 572-Trii - Drug Profile
- Antiretroviral Therapy + Pegintron - Drug Profile
- TBR 652 + Truvada - Drug Profile
- APH-0812 - Drug Profile
- Reyataz + Cobicistat - Drug Profile
- Cobicistat + Prezista - Drug Profile
- Vorinostat - Drug Profile
- HIV-1 Therapeutic Vaccine - Drug Profile
- Leukothera - Drug Profile
- BMS-663068 + Raltegravir + Tenofovir - Drug Profile
- KP-1212 - Drug Profile
- Recombinant Amphinase 2 - Drug Profile
- HIVAX - Drug Profile
- Lersivirine + Darunavir + Ritonavir + NRTI - Drug Profile
- MK-1439 - Drug Profile
- CDK9 Inhibitors - Drug Profile
- BMS-986001 + Sustiva + Lamivudine - Drug Profile
- Etravirine - Drug Profile
- VAC-3S - Drug Profile
- MazF-Based HIV-1 Gene Therapy - Drug Profile
- AFO18–CAF01 Vaccine - Drug Profile
- GTU-MultiHIV B + LIPO-5 - Drug Profile
- Rifaximin - Drug Profile
- FGI-111 Program - Drug Profile
- CLONE 3 - Drug Profile
- Atazanavir + Lamivudine + Ritonavir - Drug Profile
- HIV-1 Infection Therapeutics – Drug Profile Updates
- HIV-1 Infection Therapeutics – Discontinued Products
- HIV-1 Infection Therapeutics - Dormant Products
- HIV-1 Infection – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for HIV-1 Infection, H2 2012
- Products under Development for HIV-1 Infection – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..3)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..4)
- Bristol-Myers Squibb Company, H2 2012
- Johnson & Johnson, H2 2012
- Abbott Laboratories, H2 2012
- GlaxoSmithKline plc, H2 2012
- Inovio Biomedical Corporation, H2 2012
- Gilead Sciences, Inc., H2 2012
- Merck & Co., Inc., H2 2012
- United Biomedical, Inc., H2 2012
- Aphios Corporation, H2 2012
- Pfizer Inc., H2 2012
- Avexa Limited, H2 2012
- Koronis Pharmaceuticals, Inc., H2 2012
- Alfacell Corporation, H2 2012
- Geron Corporation, H2 2012
- GeoVax Labs, Inc., H2 2012
- ConjuChem Biotechnologies Inc., H2 2012
- Critical Outcome Technologies Inc., H2 2012
- Takara Bio Inc., H2 2012
- Functional Genetics, Inc., H2 2012
- BioClonetics Incorporated, H2 2012
- Nutri Pharma ASA, H2 2012
- Vironova AB, H2 2012
- Argos Therapeutics, Inc., H2 2012
- Myriad Pharmaceuticals, Inc., H2 2012
- GeneCure LLC, H2 2012
- Tobira Therapeutics, Inc., H2 2012
- ViiV Healthcare, H2 2012
- RFS Pharma, LLC, H2 2012
- Vichem Chemie Research Ltd., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- HIV-1 Infection Therapeutics – Drug Profile Updates
- HIV-1 Infection Therapeutics – Discontinued Products
- HIV-1 Infection Therapeutics – Discontinued Products (Contd..1)
- HIV-1 Infection Therapeutics – Dormant Products
- HIV-1 Infection Therapeutics – Dormant Products (Contd..1)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..2)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..3)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..4)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..5)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..6)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..7)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..8)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..9)
- HIV-1 Infection Therapeutics – Dormant Products (Contd..10)
- List of Figures
- Number of Products under Development for HIV-1 Infection, H2 2012
- Products under Development for HIV-1 Infection – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHIV-1 Infection – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'HIV-1 Infection - Pipeline Review, H2 2012', provides an overview of the HIV-1 Infection therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. 'HIV-1 Infection - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for HIV-1 Infection.
- A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of HIV-1 Infection therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
